Phase III study of TH-302+Gemcitabine in Pancreatic Cancer

• Research type

  Research Study

• Full title

  A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

• IRAS ID

  132252

• Contact name

  REC for Wales

• Sponsor organisation

  Merck KGaA

• Eudract number

  2012-002957-42

• ISRCTN Number

  n/a

• REC name

  Wales REC 3

• REC reference

  13/WA/0178

• Date of REC Opinion

  15 Jul 2013

• REC opinion

  Further Information Favourable Opinion